Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
Monthly Prescribing Reference

Ready-To-Use, Low IgA Gammagard Liquid ERC Approved for Primary Immunodeficiency

Commercialization of Gammagard Liquid ERC is expected to begin in 2026. The Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion [human] 10% solution) as a ...
Hosted on MSN

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in ...
Nasdaq

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...